Matthew L. Posard sold $2.0M of HALO
director at HALOZYME THERAPEUTICS, INC.. 18,996 shares at an average of $107.74, traded Sep 16, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.0M at market
- +5Share of holdings soldSold 24% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-26-000123, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -3,100 | $106.13 | $329k | 74,735 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -3,000 | $106.83 | $320k | 71,735 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -8,896 | $108.04 | $961k | 62,839 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -4,000 | $108.99 | $436k | 58,839 | 25 d ago |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 58Moderate | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $2.0M 28,857 shares | -84% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.5M 50,000 shares | -6% | |
| 15Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.9M 50,000 shares | -7% | |
| 6Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $141k 2,000 shares | -5% | |
| 44Moderate | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $278k 4,263 shares | -25% | |
| 10Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $59k 829 shares | -2% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $1.1M 16,569 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.